Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511357 | 0.84 | KDR (0.38) | KDRPIK3CDPIK3CGKDM4EPIK3CA | |
| SCHEMBL3513602 | 0.82 | KDR (0.61) | KDRPIK3CDPIK3CG | |
| SCHEMBL2860043 | 0.81 | KDR (0.52) | KDRPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL13636133 | 0.78 | KDR (0.48) | KDR | |
| SCHEMBL1931311 | 0.77 | PIK3CG (0.47) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL3510660 | 0.76 | CDK8 (0.42) | — | |
| SCHEMBL1934177 | 0.74 | PIK3CG (0.46) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL4280681 | 0.74 | KDR (0.57) | KDR | |
| SCHEMBL13636141 | 0.71 | KDR (0.52) | KDR | |
| SCHEMBL4282178 | 0.70 | BRAF (0.52) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 983/4885PIK3CD 239/4885PIK3CG 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.